Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TYR | P14679 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1661009 | 1.00 | TYR (0.53) | TYR | |
| SCHEMBL21159023 | 1.00 | TYR (0.53) | TYR | |
| SCHEMBL14119749 | 1.00 | TYR (0.53) | TYR | |
| SCHEMBL14119943 | 0.90 | TYR (0.56) | TYR | |
| SCHEMBL2042873 | 0.89 | — | — | |
| SCHEMBL2042877 | 0.89 | — | — | |
| SCHEMBL13553201 | 0.89 | — | — | |
| SCHEMBL14120217 | 0.89 | — | — | |
| SCHEMBL16843510 | 0.89 | — | — | |
| SCHEMBL15040799 | 0.89 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190211045-A1 | COMPOUNDS AND METHODS FOR TREATING BACTERIAL INFECTIONS | UNIV WASHINGTON (US) | 2019-07-11 | — | — | US | disclosed |
| EP-3492483-A1 | COMPOUNDS AND METHODS FOR TREATING BACTERIAL INFECTIONS | The Washington University (US) | 2019-06-05 | — | — | EP | disclosed |
| US-10273260-B2 | Compounds and methods for treating bacterial infections | WASHINGTON UNIVERSITY (US) | 2019-04-30 | — | — | US | disclosed |
| US-20170247401-A1 | COMPOUNDS AND METHODS FOR TREATING BACTERIAL INFECTIONS | WASHINGTON UNIVERSITY | 2017-08-31 | — | — | US | disclosed |
| US-9567362-B2 | Compounds and methods for treating bacterial infections | WASHINGTON UNIVERSITY (US) | 2017-02-14 | — | — | US | disclosed |
| US-20150197538-A1 | COMPOUNDS AND METHODS FOR TREATING BACTERIAL INFECTIONS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2015-07-16 | — | — | US | disclosed |
| US-8937167-B2 | Compounds and methods for treating bacterial infections | WASHINGTON UNIVERSITY (US) | 2015-01-20 | — | — | US | disclosed |
| US-20120309701-A1 | COMPOUNDS AND METHODS FOR TREATING BACTERIAL INFECTIONS | THE WASHINGTON UNIVERSITY (US) | 2012-12-06 | — | — | US | disclosed |
| EP-2490530-A1 | COMPOUNDS AND METHODS FOR TREATING BACTERIAL INFECTIONS | The Washington University (US) | 2012-08-29 | — | — | EP | disclosed |
| WO-2011050323-A1 | COMPOUNDS AND METHODS FOR TREATING BACTERIAL INFECTIONS | THE WASHINGTON UNIVERSITY (US) | 2011-04-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10273260-B2 | Compounds and methods for treating bacterial infections | MMP8, ELANE, GUSB | TYR 270/4885 |
| US-20120309701-A1 | COMPOUNDS AND METHODS FOR TREATING BACTERIAL INFECTIONS | MMP8, ELANE, GUSB | TYR 270/4885 |
| US-20170247401-A1 | COMPOUNDS AND METHODS FOR TREATING BACTERIAL INFECTIONS | MMP8, ELANE, GUSB | TYR 270/4885 |
| US-20190211045-A1 | COMPOUNDS AND METHODS FOR TREATING BACTERIAL INFECTIONS | MMP8, ELANE, GUSB | TYR 270/4885 |
| US-20150197538-A1 | COMPOUNDS AND METHODS FOR TREATING BACTERIAL INFECTIONS | MMP8, ELANE, GUSB | TYR 270/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.